CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
The company regained compliance with the Nasdaq minimum bid price requirement and plans to address remaining listing standards by December 2026 while advancing clinical programs.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed